Fernanda Teles’ Post

Attention pharmaceutical industry leaders! Don't miss out on the exciting opportunity to take advantage of Puerto Rico's long-term tax incentives. Explore how these incentives can benefit your company and propel your success in the ever-evolving pharmaceutical landscape. #PharmaIndustry #TaxIncentives #BusinessAdvantage

Seeking a competitive edge in the pharmaceutical sector? Puerto Rico offers attractive long-term tax incentives that can give your business a significant boost. Learn more about how these incentives can create a favorable environment for drug development and manufacturing. #PharmaSolutions #BusinessGrowth #TaxAdvantages

Puerto Rico redefined its economic landscape for the pharmaceutical sector with Act 60. Discover how Act 60 is transforming Puerto Rico to benefit pharmaceutical businesses coming to the island. #PharmaceuticalIndustry #PuertoRico #TaxIncentives #Act60

“Pharmaceutical companies comprise a significant portion of the companies engaged in #taxavoidance. In 2022, major US pharmaceutical companies reported more than $214 billion in revenue and only $10 billion in profits in the United States. Those same companies reported more than $171 billion in foreign revenue and more than $90 billion in profits overseas, despite the fact that Americans pay the highest pharmaceutical costs in the world” #Pfizer #Ireland #Netherlands #CPPharmaceuticalsInternationalCV #Bermuda #CaymanIslands https://lnkd.in/eXc88MkY

Paying fair share of taxes reduces the tax burden. Australia needs tax reform from.ground up to be tied to government expenditure and government savings for future of Australians. Other countries have sovereign funds including investments in Australia. Australian government debt has reached $1 trillion dollars plus $350bikkion dollars unfunded public service superannuation. Let's be fair and start taking car of Australia first

Pharma supply chain resilience strategies need to consider tax implications. https://okt.to/vw2eOq #LSHC #pharmasupplychain #supplychainresilience #pharmaceuticals #supplychaindisruptions

Clinical Trials: Preparing for your Clinical Trial Cycle 💊 If you are a US or Canadian based Pharmaceutical, Biotechnology, or Therapeutics business gearing up to start your clinical trials within Europe, please be prepared for the VAT implications you will encounter. VAT is a tax charged in Europe, very similar to GST here in the US. This is not an Opt-in or Opt-out cost, your business will be charged this VAT at some point and you will have to pay it. The positive side to this is that there is an opportunity to recover it back! However, as much as they say European UNION, there isn't much unity about it as each country has it's own set of complex laws and requirements to recover the VAT. Tax is never a fun subject, but it's important. This area of tax (VAT) can get your business back a significant amount of money, especially when working on tight budgets. If you have upcoming or current trials in Europe and you would like to learn more on this VAT, why it is charged and how you can get it back. Please feel free to reach out to me directly: dale@vatitusa.com (757) 617 6329. https://lnkd.in/dDChYAkB #pharmaceutical #biotechnology #therapeutics #clinicaltrials #testing #import #vat #europe #logistics

Thoughts on this? >> Teva to pay $750M to resolve Israel tax disputes >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharmaceutical #pharma #healthcare

RECCE uses innovative method to bring forward R&D The federal government’s Research and Development (R&D) tax incentive may have highly restrictive rules and definitions which cut the number of companies eligible for assistance, but for early stage and start up companies it can be a godsend. But it is something paid after the expenditure is already made, stretching cash flow for many. Anti-infective drug development company Recce Pharmaceuticals is one of a growing group of companies using an innovative way of bringing forward payments expected through the R&D tax incentive The company, which is developing a new class of Synthetic Anti-Infectives, today announced approval for $11,178,965 as an R&D Advance payment from Endpoints Capital capturing tax incentive for FY23/24 and FY25. #manufacturing #manufacturingnews #grants #innivation @ReccePharma Recce Pharmaceuticals Ltd https://lnkd.in/gcJTfZTr

Thoughts on this? >> Teva to pay $750M to resolve Israel tax disputes >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #productmarketing #pharmaceutical